Pharmacotherapy in Psychiatry and Neurology
eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Ethical standards and procedures Reviewers Instructions for authors
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

without publication fees

Open access

without publication fees
2/2025
vol. 41
 
Share:
Send email
Share:
Review article

Treatment of bipolar disorder in pediatric population

Weronika D. Pawlak-Łukaszek
1
,
Martyna P. Bień
1, 2
,
Lena Cichoń
1, 2
,
Małgorzata Janas-Kozik
1, 2

  1. The John Paul II Child and Family Health Centre in Sosnowiec Ltd., Sosnowiec, Poland; Centrum Zdrowia Dziecka i Rodziny im. Jana Pawła II w Sosnowcu Sp. z o.o., Sosnowiec, Polska
  2. Department and Clinical Unit of Psychiatry and Psychotherapy of Developmental Age, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, Poland; Katedra i Oddział Kliniczny Psychiatrii i Psychoterapii Wieku Rozwojowego, Śląski Uniwersytet Medyczny w Katowicach, Katowice, Polska
Farmakoterapia w Psychiatrii i Neurologii 2025
DOI: https://doi.org/10.5114/fpn.2025.160138
Online publish date: 2026/04/28
Article file
- Treatment of bipolar disorder in paediatric population.pdf  [0.57 MB]
Get citation
 
PlumX metrics:
 
1. Arypiprazol. Charakterystyka produktu leczniczego; https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/34036/characteristic.
2. Calabrese JR, Pikalov A, Streicher C, Cucchiaro J, Mao Y, Loebel A. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol 2017; 27: 865–876.
3. Chokhawala K, Lee S, Saadabadi A. Lithium. National Center for Biotechnology Information. National Library of Medicine 2024; (dostęp 18.11.2025).
4. Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45 (3): 298–304.
5. Cichon L, Janas-Kozik M, Siwiec A, Rybakowski JK, Cichon L, Janas-Kozik M, et al. Clinical picture and treatment of bipolar affective disorder in children and adolescents. Psychiatr Pol 2020; 54 (1): 35–50.
6. Colom F, Vieta E. Podręcznik psychoedukacji w zaburzeniach afektywnych dwubiegunowych. Warszawa: Medipage, 2009.
7. DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. BipolarDisord 2009; 11 (5): 483–493.
8. DelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A. Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study. J Am Acad Child Adolesc Psychiatry 2017; 56 (12): 1015–1025.
9. DelBello MP, Kadakia A, Heller V, Singh R, Hagi K, Nosaka T et al. Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression. J Am Acad Child Adolesc Psychiatry 2022; 61 (2): 243–254.
10. DelBello MP, Tocco M, Pikalov A, Deng L, Goldman R. Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression. J Child Adolesc Psychopharmacol 2021; 31 (7): 494–503.
11. Findling RL, Çavuş I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK et al. Efficacy, Long-Term Safety, and Tolerability of Ziprasidone in Children and Adolescents with Bipolar Disorder. J Child Adolesc Psychopharmacol 2013; 23 (8): 545.
12. Findling RL, Landbloom RL, Mackle M, Wu Xiao, Snow-AdamiSnow-Adami L, Chang K. Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial. Paediatr Drugs 2016; 18 (5): 367–378.
13. Findling RL, Earley W, Suppes T, Patel M, Wu X, Chang CT et al. Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: Efficacy related to mixed or manic episode, stage of illness, and body weight. Neuropsychiatr Dis Treat 2018; 14: 1941–1952. (a)
14. Findling RL, Stepanova E, Youngstrom EA, Young AS. Progress in diagnosis and treatment of bipolar disorder among children and adolescents: An international perspective. Evid Based Ment Health 2018; 21 (4): 177–181. (b)
15. Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier P et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. International Journal of Neuropsychopharmacology 2016 Feb 1; 20 (2): 180–195.
16. Fristad MA, MacPherson HA. Evidence-Based Psychosocial Treatments for Child and Adolescent Bipolar Spectrum Disorders. J Clin Child Adolesc Psychol 2014; 43 (3): 339–55.
17. Fristad MA, Verducci JS, Walters K, Young ME. Impact of multifamily psychoeducational psychotherapy in treating children aged 8 to 12 years with mood disorders. Arch Gen Psychiatry 2009; 66 (9): 1013–1021.
18. Goldstein BI, Birmaher B, Carlson GA, DelBello MP, Findling RL, Fristad M et al. The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: Knowledge to date and directions for future research. Bipolar Disord 2017; 19 (7): 524–543.
19. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes TRH, Cipriani A et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30 (6): 495–553.
20. Grabski B, Mączka G, Dudek D. The role of psychoeducation in the complex treatment of bipolar disorder. Arch Psychiatry Psychother 2007; 9 (3): 35–41.
21. Guidelines. Valproate – reproductive risks. Information about the reproductive risks of taking valproate medicines and the measures in place to reduce potential harm. 2025;
22. https://www.gov.uk/guidance/valproate-reproductive-risks (dostęp 18.11.2025).
23. Janas-Kozik M, Wolańczyk (red. nauk.). Psychiatria Dzieci i Młodzieży. PZWL Wydawnictwo Lekarskie, Warszawa 2023.
24. Joshi G, Petty C, Wozniak J, Faraone SV, Spencer AE, Woodworth KY et al. A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents. Psychopharmacology 2013 Feb; 227 (3): 449–458.
25. Keramatian K, Chakrabarty T, Saraf G, Yatham LN. New Developments in the Use of Atypical Antipsychotics in the Treatment of Bipolar Disorder: a Systematic Review of Recent Randomized Controlled Trials. Curr Psychiatry Rep 2021; 23 (7).
26. Keramatian K, Chithra NK, Yatham LN. The CANMAT and ISBD Guidelines for the treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence. Focus: Journal of Life Long Learning in Psychiatry 2023; 21 (4): 344–353.
27. Lewandowska A, Janas-Kozik M, Tyszkiewicz-Nwafor M, Dudek D, Gałecki P, Remberk B. Zaburzenie dwubiegunowe u dzieci, młodzieży i młodych dorosłych. Część 2. Rekomendacje pod patronatem Zarządu Głównego Polskiego Towarzystwa Psychiatrycznego oraz Konsultantów Krajowych w dziedzinie psychiatrii i psychiatrii dzieci i młodzieży; Psychiatr Pol 2025; 59 (3): 359–372.
28. Lithium carbonicum. Charakterystyka produktu leczniczego; https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/3943/characteristic.
29. Lorafen. Charakterystyka produktu leczniczego; https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/3971/characteristic/.
30. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacother 2004; 24 (9): 1177–1185. 
31. Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003; 60 (9): 904–912.
32. Miklowitz DJ, Taylor DO. Bipolar Disorder in Childhood and Adolescence. Handb Depress Adolesc 2008; 26 (Suppl 3): 179–205.
33. Nandagopal JJ, DelBello MP, Kowatch R. Pharmacologic Treatment of Pediatric Bipolar Disorder. Child Adolesc Psychiatr Clin N Am 2009; 18 (2): 455–469.
34. National Institute of Health and Care Excellence, CG185; https://www.nice.org.uk/guidance/cg185.
35. National Institute of Health and Care Excellence, TA292; https://www.nice.org.uk/guidance/ta292.
36. Neorelium. Charakterystyka produktu leczniczego; https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/5775/characteristic.
37. O’brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 2005: 66 Suppl 2: 28–33.
38. Paliperidone +pharma. Charakterystka produktu leczniczego; https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/50584/characteristic (dostęp 15.12.2025).
39. Patel NC, DelBello MP, Bryan HS, Adler CM, Kowatch RA, Stanford K et al. Open-label lithium for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45 (3): 289–297.
40. Poweleit EA, Colestock M, Kantemneni EC, Strawn JR, Patino LR, DelBello MP et al. Cariprazine in Youth with Bipolar and Psychotic Disorders: A Retrospective Chart Review. J Child Adolesc Psychopharmacol 2020; 30 (4): 267–272.
41. Riccobene T, Riesenberg R, Yeung PP, Earley WR, Hankinson AL. Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia. J Child Adolesc Psychopharmacol 2022; 32 (8): 434–443.
42. Sajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio R. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv 2007; 58 (6): 855–863.
43. Singh B, Swartz HA, Cuellar-Barboza AB, Schaffer A, Kato T, Dols A, Sperry SH, Vassilev AB, Burdick KE, Frye MA. Bipolar disorder. The Lancet 2025; 406 (10506): 963–978.
44. Singh MK, Pikalov A, Siu C, Tocco M, Loebel A. Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Post Hoc Analysis of a Randomized Placebo-Controlled Trial. J Child Adolesc Psychopharmacol 2020; 30 (10): 590–598.
45. Stepanova E, Grant B, Findling RL. Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review. Pediatr Drugs 2018; 20 (2): 121–34.
46. Szegedi A, Durgam S, Mackle M, Yun Yu S, Wu X, Mathews M et al. Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry 2018; 175 (1): 71–79.
47. Taylor DO, Miklowitz DJ. Bipolar Disorder in Childhood and Adolescence. Handb Depress Adolesc 2008; 26 (Suppl 3): 179–205.
48. Vita G, Nöhles VB, Ostuzzi G, Barbui C, Tedeschi F, Heuer FH et al. Systematic Review and Network Meta-Analysis: Efficacy and Safety of Antipsychotics vs Antiepileptics or Lithium for Acute Mania in Children and Adolescents. J Am Acad Child Adolesc Psychiatry 2025; 64 (2): 143–157.
49. Walker DJ, DelBello MP, Landry J, D’Souza DN, Detke HC. Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination. Child Adolesc Psychiatry Ment Health 2017; 11 (1): 1–12.
50. Wozniak J, O’Connor H, Iorini M, Ambrose AJH. Pediatric Bipolar Disorder: Challenges in Diagnosis and Treatment. Pediatric Drugs 2025; 27 (2): 125–142.
51. Zagorski N. FDA Approves Latuda for Bipolar Depression in Children and Adolescents. Psych News 2018; 4 (dostęp 14.12.2025).
52. Zypsila. Charakterystyka produktu leczniczego; https://leki.urpl.gov.pl/files/43_Zypsila_kaps_tw_80mg.pdf (dostęp 02.12.2025).

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.